Friday, 16 October 2026European Markets

KORIAN Stock Bearish By 19% At Session Start On Wednesday

Loading stream...

(vianews) - shares of korian (cac 40: kori.pa) slid by a staggering 19.39% to €7.69 at 10:54 est on wednesday, following the last session's upward trend. cac 40 is sliding 0.89% to €7,243.92, after three consecutive sessions in a row of losses. this seems, as yet, a somewhat down trend exchanging session today.

about korian

korian provides a range of medical and non-medical care and support services for the elderly and people with short or longer-term health issues. the company operates long-term care nursing homes, specialized clinics, and assisted living and shared housing facilities for seniors, as well as offers home care, support, and hospitalization services. as of december 31, 2021, it operated with 91,808 beds. the company operates approximately 850 care facilities and networks in france, germany, italy, spain, the netherlands, and belgium. the company was formerly known as korian-medica s.a. and changed its name to korian in july 2015. korian was founded in 2001 and is based in paris, france.

earnings per share

as for profitability, korian has a trailing twelve months eps of €0.3.

pe ratio

korian has a trailing twelve months price to earnings ratio of 25.55. meaning, the purchaser of the share is investing €25.55 for every euro of annual earnings.

volatility

korian's last week, last month's, and last quarter's current intraday variation average was a positive 1.01%, a negative 0.13%, and a positive 1.80%.

korian's highest amplitude of average volatility was 2.11% (last week), 1.80% (last month), and 1.80% (last quarter).

volume

today's last reported volume for korian is 2316093 which is 394.72% above its average volume of 468157.

more news about korian (kori.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com